Bone Marrow Assessment and Survival in Dogs with Blood Disorders
Author Information
Author(s): Meredith Anna M., Beeler-Marfisi Janet, Berke Olaf, Mutsaers Anthony J., Bienzle Dorothee
Primary Institution: University of Guelph
Hypothesis
A diagnosis of MDS versus AML, a lower blast percentage in blood or marrow, and a milder degree of cytopenia would be associated with longer survival.
Conclusion
Dogs with myelodysplastic syndrome (MDS) have a significantly longer survival compared to those with acute myeloid leukemia (AML).
Supporting Evidence
- Dogs with MDS had a median survival of 384 days, while those with AML had a median survival of only 6 days.
- Significant predictor variables of survival included body weight, white blood cell count, platelet count, and percent blood blasts.
- The risk of death for dogs with MDS was approximately 5 times lower than that of dogs with AML.
Takeaway
This study looked at sick dogs to see how long they lived based on their blood problems, finding that some types of blood issues are easier to treat than others.
Methodology
The study involved a database search for cases of MDS or AML, applying exclusion criteria, and assessing outcomes based on hematologic and morphologic evaluations.
Potential Biases
Potential bias due to the retrospective nature and reliance on historical medical records.
Limitations
The study is retrospective, and some cases of myeloid neoplasia may not have been coded correctly; treatment effects were not fully controlled.
Participant Demographics
Dogs diagnosed with MDS or AML, with a variety of breeds and ages, primarily mixed breeds.
Statistical Information
P-Value
<0.001
Confidence Interval
[1, 15]
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website